- Home
- BZUN vs INZY Comparison
BZUN vs INZY Comparison
Compare BZUN & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- INZY
- Stock Information
- Founded
- BZUN 2007
- INZY 2015
- Country
- BZUN China
- INZY United States
- Employees
- BZUN N/A
- INZY N/A
- Industry
- BZUN Catalog/Specialty Distribution
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- INZY Health Care
- Exchange
- BZUN Nasdaq
- INZY Nasdaq
- Market Cap
- BZUN 131.7M
- INZY 256.3M
- IPO Year
- BZUN N/A
- INZY 2020
- Fundamental
- Price
- BZUN $2.61
- INZY N/A
- Analyst Decision
- BZUN Buy
- INZY Buy
- Analyst Count
- BZUN 2
- INZY 9
- Target Price
- BZUN $3.20
- INZY $15.22
- AVG Volume (30 Days)
- BZUN 262.6K
- INZY 989.2K
- Earning Date
- BZUN 08-27-2025
- INZY 08-05-2025
- Dividend Yield
- BZUN N/A
- INZY N/A
- EPS Growth
- BZUN N/A
- INZY N/A
- EPS
- BZUN N/A
- INZY N/A
- Revenue
- BZUN $1,310,110,798.00
- INZY N/A
- Revenue This Year
- BZUN $5.27
- INZY N/A
- Revenue Next Year
- BZUN $3.46
- INZY N/A
- P/E Ratio
- BZUN N/A
- INZY N/A
- Revenue Growth
- BZUN 6.77
- INZY N/A
- 52 Week Low
- BZUN $2.11
- INZY $0.72
- 52 Week High
- BZUN $4.38
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- BZUN 46.57
- INZY 82.67
- Support Level
- BZUN $2.48
- INZY $3.94
- Resistance Level
- BZUN $2.70
- INZY $3.97
- Average True Range (ATR)
- BZUN 0.15
- INZY 0.01
- MACD
- BZUN 0.00
- INZY -0.08
- Stochastic Oscillator
- BZUN 29.18
- INZY 100.00
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.